WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406731
CAS#: 330161-87-0
Description: SU6656 is a potent and selective dual inhibitor of Src family kinases and Aurora kinase. SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner. SU6656 induces caspase-independent cell death in FRO anaplastic thyroid carcinoma cells and therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo.
Hodoodo Cat#: H406731
Name: SU6656
CAS#: 330161-87-0
Chemical Formula: C19H21N3O3S
Exact Mass: 371.13
Molecular Weight: 371.450
Elemental Analysis: C, 61.44; H, 5.70; N, 11.31; O, 12.92; S, 8.63
Synonym: SU6656; SU 6656; SU-6656.
IUPAC/Chemical Name: (Z)-N,N-dimethyl-2-oxo-3-((4,5,6,7-tetrahydro-1H-indol-2-yl)methylene)indoline-5-sulfonamide
InChi Key: LOGJQOUIVKBFGH-YBEGLDIGSA-N
InChi Code: InChI=1S/C19H21N3O3S/c1-22(2)26(24,25)14-7-8-18-15(11-14)16(19(23)21-18)10-13-9-12-5-3-4-6-17(12)20-13/h7-11,20H,3-6H2,1-2H3,(H,21,23)/b16-10-
SMILES Code: O=S(C1=CC2=C(NC(/C2=C\C(N3)=CC4=C3CCCC4)=O)C=C1)(N(C)C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 371.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Cicha I, Zitzmann R, Goppelt-Struebe M. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner. Int J Biochem Cell Biol. 2014 Jan;46:39-48. doi: 10.1016/j.biocel.2013.11.014. Epub 2013 Nov 22. PubMed PMID: 24275091.
2: Ondrušová L, Réda J, Záková P, Tuháčková Z. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells. Folia Biol (Praha). 2013;59(4):162-7. PubMed PMID: 24093774.
3: Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm Metab Res. 2013 Jun;45(6):408-14. doi: 10.1055/s-0033-1333716. Epub 2013 Feb 5. PubMed PMID: 23386415.
4: Arai R, Tsuda M, Watanabe T, Ose T, Obuse C, Maenaka K, Minami A, Ohba Y. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo. Eur J Cancer. 2012 Oct;48(15):2417-30. doi: 10.1016/j.ejca.2011.12.028. Epub 2012 Jan 13. PubMed PMID: 22244830.
5: Yoshida K, Ono M, Bito H, Mikami T, Sawada H. Plasmodium induced by SU6656, an Src family kinase inhibitor, is accompanied by a contractile ring defect. Cell Biochem Funct. 2012 Jan;30(1):33-40. doi: 10.1002/cbf.1814. Epub 2011 Oct 27. PubMed PMID: 22034098.
6: Riffell JL, Jänicke RU, Roberge M. Caspase-3-dependent mitotic checkpoint inactivation by the small-molecule inducers of mitotic slippage SU6656 and geraldol. Mol Cancer Ther. 2011 May;10(5):839-49. doi: 10.1158/1535-7163.MCT-10-0909. Epub 2011 Mar 25. PubMed PMID: 21441410.
7: Kaminska J, Klimczak-Jajor E, Skierski J, Bany-Laszewicz U. Effects of inhibitor of Src kinases, SU6656, on differentiation of megakaryocytic progenitors and activity of alpha1,6-fucosyltransferase. Acta Biochim Pol. 2008;55(3):499-506. Epub 2008 Sep 15. PubMed PMID: 18854874.
8: Dussault N, Simard C, Néron S, Côté S. Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656. Blood Cells Mol Dis. 2007 Jul-Aug;39(1):130-4. Epub 2007 Apr 16. PubMed PMID: 17434768.
9: Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, Fu A, Shyr Y, Wu H, Hallahan DE. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1197-203. PubMed PMID: 16504759.
10: Lannutti BJ, Blake N, Gandhi MJ, Reems JA, Drachman JG. Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. Blood. 2005 May 15;105(10):3875-8. Epub 2005 Jan 27. PubMed PMID: 15677565; PubMed Central PMCID: PMC1895086.
11: Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27. PubMed PMID: 11074000; PubMed Central PMCID: PMC86555.